GET DAILY SIGNALSBeOne Medicines (ONC) Advances +12% in 30 Days on Strong Q3 Results
Key Takeaways
- BeOne Medicines (ONC) climbed roughly 12% over the last 30 days, rising from a closing price near $364 in early October to above $408 on the most recent trading session.
- The move extends a broader rally, with the stock up about 24% over the past three months.
- Strong third-quarter 2026 results were a key catalyst, with total revenue up 34% year over year and net income rising more than 200%.
- Sales of its flagship blood-cancer treatment BRUKINSA grew approximately 34% year over year, reinforcing the company's commercial momentum.
- Regulatory progress, including a U.S. FDA approval for TEVIMBRA and a U.S. government access agreement, supported investor sentiment.
BeOne Medicines (ONC) Company Snapshot
BeOne Medicines AG is a global oncology company focused on discovering, developing, and commercializing treatments for blood cancers and solid tumors. Formerly known as BeiGene, Ltd., the company changed its name and moved its headquarters to Basel, Switzerland in 2025. Its portfolio centers on BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor for various blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy for solid tumors and blood cancers. Additional products include XGEVA and SYLVANT.
Investors track ONC for its established commercial presence across the United States, China, Europe, and other regions, along with a pipeline that includes Bcl-2 inhibitors, antibody-drug conjugates, and other oncology candidates. The transition to a revenue-generating business with an expanding global footprint stands out in the sector.
Stock Performance: +12% Over 30 Days and +24% Over the Quarter
Over the past 30 days, ONC gained approximately 12%, advancing from a close near $364 in early October to more than $408 in the latest session. The path was not linear, with a brief dip into the mid-$340s early in the period before a steady recovery through late October and into early November.
The three-month view shows even clearer strength. From a level near $330 in early August, the shares have risen roughly 24%, supported by better fundamentals and a series of positive regulatory and commercial updates. Momentum in November carried the stock toward the upper end of its recent range.
Drivers of the Recent 30-Day Advance
The third-quarter 2026 earnings release stood out as the main catalyst. Total revenue reached roughly $1.9 billion, up 34% year over year, while net income more than doubled from the prior-year period. BRUKINSA sales grew about 34% year over year, with TEVIMBRA and products such as XGEVA adding to the total. Cash, cash equivalents, and restricted cash stood at approximately $5.9 billion at quarter-end.
Additional developments helped sentiment. In late August the U.S. Food and Drug Administration approved TEVIMBRA in combination regimens for a form of stomach cancer. The company also reached a voluntary agreement with the U.S. government to improve patient access and announced a clinical collaboration with Revolution Medicines to study new combinations. These factors contributed to the decisive move higher in early November. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Broader Drivers Behind the Three-Month Rally
The roughly 24% gain over the past quarter reflects steady financial improvement and consistent execution on both commercial and pipeline fronts. The shift from a research-focused biotech to a profitable commercial business has become more visible, with BRUKINSA and TEVIMBRA delivering reliable revenue growth.
Over the period, investors responded to expanding regulatory approvals, deeper penetration in the U.S. market, and progress across clinical-stage assets. The ability to fund internal research from operating cash flow and strategic partnerships with larger pharmaceutical companies have also supported the narrative.
What to Watch Next for ONC
Looking forward, attention will likely center on the sustainability of BRUKINSA revenue growth and the commercial uptake of TEVIMBRA after its expanded approval. Upcoming earnings and guidance will help gauge whether margin expansion can continue. Pipeline progress, including Bcl-2 inhibitors and the outcome of the collaboration with Revolution Medicines, may also influence sentiment.
Broader considerations include the competitive oncology landscape, macroeconomic effects on healthcare spending, and regulatory or reimbursement changes in key markets. The company’s substantial cash position offers flexibility, but execution on commercial and clinical goals will remain critical.
Exploring AI-Assisted Trading Strategies
One resource I turn to regularly is Tickeron’s AI Trading Bots. The platform offers a range of automated strategies that monitor thousands of tickers, each with different timeframes and performance metrics. Reviewing the active bots provides additional perspective on how data-driven approaches are navigating names like ONC right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ONC in -4.14% downward trend, falling for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONC declined for three days, in 239 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ONC moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 26 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 64 cases where ONC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on ONC as a result. In 60 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ONC just turned positive on November 05, 2026. Looking at past instances where ONC's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
ONC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ONC crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONC advanced for three days, in 224 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ONC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 192 of 260 cases where ONC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ONC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.467) is normal, around the industry mean (2.788). P/E Ratio (66.197) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.776) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (6.553) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceutical products
Industry Biotechnology
Advertisement